Member Info for WelshFalcon

I doubt it @BV.

If they did have a peek, the Trump like name calling non arguments would kill any credibility they could ascribe to any postings on here!

It's simple maths.

Say the amount we need to pay is £2,000,000

We pay in cash - cash that was raised in the 50p raise. This represents 4,000,000 of the shares raised (4m*50p) Simples.

We pay in shares at, say 80p. this represents 2,500,000 shares to cover the £2m at 80p. Simples.

IF there is new cash in the coffers, (sale of DX, or other deal) then use cash.

If not, then we have diluted at 50p and then taken that cash to pay double for an expense we didn't raise the cash for! Madness.

You can be as confident as you like....

In the absence of any additional source of cash in the coffers you will be paying with expensive cash that was raised at at 50p. I.e. the net cost to shareholders will be double!

All it would demonstrate is poor cash management with a cheaper option of shares (at more than 50p, obviously).

The cash was raised for a purpose - has that purpose gone away?

If there is a deal with new cash in the coffers, then it makes sense - as we stand at the moment it would be very poor management to use our expensive cash.

Emotive carp.

Deal first. If a deal is signed, then that makes sense.

Currently there is no deal announced - so you are speculating.

Cash or shares?

Stop being emotive....look at the real numbers.

The cash raise was at 50p. Fact.

If they settle in cash, then they will have effectively diluted at 50p. i.e. AVCT will spend (expensive) cash which may be needed to progress the company.

If they settle in share at anything above 50p, this will be lower dilution than already achieved in the cash raise and will leave the cash available to progress the company.

Settling in shares (above 50p) is actually better and cheaper than using our 50p raised cash.

Everything else is emotive dribble creating a very odd narrative. Look to the numbers - if they settle in cash with a share value north of 50p, then this would be a bad business decision and will put up a massive red flag for me!

Short, not sort. Obviously!

They can time it however they wish, it's their sort and their problem...

If they decide to wait for heights..... then what price will it be then? Could be higher, could be lower.... Sounds like (to me) doubling down on a large bet if they wait too long!

Good to see.

Now that they have started to move their position, they still have a long way to fully close out. This will hopefully provide some nice buying impetus.

Breached, at last!

Https://www.google.com/finance/quote/AVCT:LON?hl=en

It's a pattern I've never seen before. A hard stop at 85 with the dips climbing progressively higher...

Watching today's chart, it's looking like a hard stop at 85, what happens if we breach this ceiing?

Still showing at .81% this morning......

Even after the recent stellar performance!

Oh my!

You know what the 'I' in IPO stands for, don't you?

We are already listed.......

This baby is constantly kicking at my 71 average.

Open the door, let her out now....

There's more than one.

I believe the second one, obviously!

Elephant in the room..... LMAO.

A pink elephant flying around in his head more like.

Actually, if you think about it, a short half life is a massive advantage!

So, we know that Dox is being delivered in therapeutically relevant doses. This has been shown.

With a short half life (in minutes, as has been suggested) you could potentially hit the tumour with a 1 2 3 punch all in the same day. 1st dose at 9 am, 2nd at say, 13:00, third at 5pm and send patient home. Scan him after a week or two to be able to tell him all is sorted....

Now wouldn't that be wonderful.

He's just trying to create a negative narrative where there isn't one.

The half life isn't an issue at all. The aim of the game is to get as much Dox (or other warhead) into the tumour. Proven to be done effectively. In this way the half life manufactured issue is irrelevant, the results show that the aim is on target.

However, AVCT are looking at working on the half life (see patents post), If they can improve here the effect would be to get the same amount of Dox delivered to the tumour with a lower dose and consequent improvement (reduction) in any residual side effects. This will also enable lower and even more frequent dosing.

So you can safely ignore all his protestations re half life etc. It is simply an irrelevant diversion.

That's for close of play today, of course!

Bit of fun for a Friday.

How close will we get to 60 (+ or -).

My bid is -1.76 (58.24)